Navigation Links
Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
Date:3/16/2009

orted back to physicians within two to three days. Subscribing physicians may also view their test results over the Internet. For more information, please visit www.ibsbloodtest.com.

About IBS

According to the National Institute of Diabetes and Digestive and Kidney Diseases, in 2007, almost 60 million, or 20%, of the U.S. population had symptoms of IBS, making it one of the most common disorders diagnosed by physicians. At least twice as many women as men are affected by IBS, a disorder characterized most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. Although it significantly impairs health-related quality of life, many people suffer from IBS for years before being properly diagnosed and treated. It is believed that up to 75% of people suffering from IBS are not receiving medical care for their symptoms, due in part to the current difficulties of diagnosing IBS.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is currently focused on the detection, diagnosis and treatment of gastrointestinal diseases and disorders in the United States. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
2. Prometheus Licenses COLAL-PRED(R) From Alizyme
3. Catilin Receives Renewable Energy Award for Pilot Plant
4. Avon Protection Systems Receives NIOSH Approval for ST53 SCBA System
5. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
6. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
7. AMPAC Fine Chemicals Receives the California Pollution Prevention Challenge Award Two Consecutive Years
8. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
9. Advanced Life Sciences Receives Notice of Planned Cethromycin Review by FDA Advisory Committee
10. Serica Technologies Receives FDA 510(k) Clearance for SeriScaffold(TM) Technology for Soft Tissue Repair
11. Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... In her thought provoking debut novel ... to a not-so-distant future faced with an Ebola pandemic that is on the cusp ... tragedy to enter the world of counterterrorism, and who continues to appear in this ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... in the neuro and pain management space join prominent academics and key investors ... Center at Harvard Medical School in Boston. , Neuro Advance Boston focuses ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new ... by researchers at the Keck Graduate Institute and its collaborators. The discovery has ... findings were published online on August 27 by Scientific Reports, an open access ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply ... risk management and resiliency practitioners with luminaries and thought leaders to advance the ... recognized for their innovations and performance excellence. At that time its principle sponsor, ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
Biology Products: